Duke University has expanded its presence on the North Carolina Research Campus to support its work with Google and other partners.
Alexion Pharmaceuticals has turned to Big Data specialist BioXcel for help identifying its next blockbuster rare disease drug. BioXcel is applying its rare disease database to the collaboration, which aims to figure out which indications are most likely to benefit from various therapeutics.
The Google X lab that spawned smart contact lenses and self-driving cars is teaming up with Biogen Idec to unravel patient-to-patient variation in the progression of multiple sclerosis.
Box has added a big-name client just days after pulling off a $175 million IPO. The deal sees AstraZeneca join Allergan and Eli Lilly on the list of major biopharma companies that use Box's cloud content sharing and collaboration tools.
The European Medicines Agency (EMA) has taken another step toward the creation of a database of all suspected adverse reactions reported within its jurisdiction. The EMA laid out the technical details of the system and how it will affect biopharma companies in a 100-page guide it published this week.
Juniper Research analyst James Moar told Outsourcing-Pharma the placing of limits on the types of information that can have medical uses will slow uptake.
Study startup specialist goBalto is preparing to up its game in Asia. The San Francisco, CA-based software developer outlined the strategy after raising $12 million from new backers, including Japan's Mitsui Global Investment.
President Obama has pushed precision medicine and cybersecurity into the national consciousness and toward the top of the legislative agenda. Obama referred to both topics in his State of the Union address, but at this stage more is known about the cybersecurity plan.
Anyone with a passing interest in tech startups is unlikely to be shocked by Silicon Valley VC Andreessen Horowitz listing digital health as one of its top 16 trends. But as one of the organizations with some power over how these trends play out, the reasoning behind Andreessen Horowitz's list makes for interesting reading.
Last year the campaign for Chimerix to give an experimental cancer drug to a 7-year-old gave biopharma firms another reason to be wary of the power of social media. Having seen Chimerix be engulfed by the social media maelstrom, BIO is working to equip small biotechs with the skills they will need if they find themselves in a similar situation.
The deal gives Novartis access to the most active digital health VC team--Rock Health reports Qualcomm Ventures has struck 21 deals since 2011--and further strengthens the ties between the two companies.
10X Genomics has exited stealth mode with $80 million in VC funding and a plan to solve a significant sequencing problem without going head to head with Illumina. The Pleasanton, CA-based startup is set to unveil an add-on for Illumina sequencers that improves their ability to map long reads of DNA.
Personalis has returned to the financing font ahead of a planned scaling up of its operations. The Menlo Park, CA-based genome sequencing and interpretation company has reported interest from pharma companies in its cancer services, a trend that helped persuade investors to give it $33 million in a Series C round.
The clinical trial data transparency movement was propelled forward by two major developments this week. On the same day, influential national academy the Institute of Medicine called for more systematic sharing of trial results and Johnson & Johnson agreed to extend its transparency initiative to include medical devices and diagnostics.
Having given a $60 million boost to 23andMe last week, Genentech has now turned to J. Craig Venter's Human Longevity for help sequencing and analyzing tens of thousands of genomes.
Days after unveiling a $60 million deal with Genentech, personal genomics pioneer 23andMe struck a new database-driven collaboration with Pfizer. There is even talk of a possible resolution with the FDA in 2015.
NextCODE has made a sharp exit. Just 15 months after some ex-deCode Genetics executives struck a deal with Amgen to create NextCODE, Chinese CRO WuXi PharmaTech has bought the genomic analysis startup for $65 million in cash.
Novartis has added another component to its "Clinical Trials of the Future" program. The latest element of the trial efficiency initiative sees the Swiss Big Pharma team up with computer chip maker Qualcomm to gather data on clinical trial participants between visits to the investigator site.
The FDA has released a list of almost 100 draft drug guidance documents it plans to introduce or update in 2015. The documents cover a range of biotech IT-related topics, including electronic informed consent in clinical trials, links to third-party sites in social media adverts and statistical approaches to showing biosimilarity.
Adaptive Biotechnologies is keeping its foot on the gas. Having raised $105 million from VCs in April, the immune sequencing firm has now added a further $94 million and bought Sequenta for an undisclosed sum of cash and stock.